Compass Therapeutics Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
24
- Stock Symbol
-
CMPX
- Investments
-
2
- Share Price
-
$2.80
- (As of Friday Closing)
Compass Therapeutics General Information
Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
Contact Information
Website
www.compasstherapeutics.com
Formerly Known As
Kairos Biologics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 80 Guest Street
- Suite 601
- Boston, MA 02135
- United States
Compass Therapeutics Timeline
Compass Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.80 | $2.70 | $1.25 - $5.80 | $273M | 101M | 196K | -$1.29 |
Compass Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (1,692) | 293,396 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (80,082) | (80,216) | (26,244) | (32,048) |
| Net Income | (81,922) | (82,181) | (29,500) | (34,744) |
| Total Assets | 146,564 | 153,757 | 51,911 | 30,381 |
| Total Debt | 3,767 | 4,037 | 9,334 | 14,869 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Compass Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Compass Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics i
Drug Discovery
Boston, MA
24
As of 2021
00000
00000000
00000
000000
uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pa
0000 000000000
Burlingame, CA
00
As of 0000
00000
000000 - 000
00000
000000
eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
South San Francisco, CA
000
As of 0000
00000
00000000
00000
Add Comparison
Compass Therapeutics Competitors (105)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Venture Capital-Backed | San Carlos, CA | 00 | 00000 | 000000000000 | 00000 |
Compass Therapeutics Patents
Compass Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3127072-A1 | Formulations of antibodies that bind human cd137 and uses thereof | Pending | 16-Jan-2019 | 00000000000 | |
| AU-2020208397-A1 | Formulations of antibodies that bind human cd137 and uses thereof | Pending | 16-Jan-2019 | 00000000000 | |
| EP-3911679-A1 | Formulations of antibodies that bind human cd137 and uses thereof | Pending | 16-Jan-2019 | 00000000000 | |
| EP-3897117-A1 | Transgenic mouse expressing common human light chain | Pending | 21-Dec-2018 | 00000000000 | |
| AU-2019379576-A1 | Multispecific binding constructs against checkpoint molecules and uses thereof | Pending | 13-Nov-2018 | C07K16/2818 |
Compass Therapeutics Executive Team (13)
Compass Therapeutics Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bruce Steel | Self | Board Observer | 000 0000 |
| Carl Gordon Ph.D | Self | Chairman & Board Member | 000 0000 |
| Miranda Toledano | Self | Board Member | 000 0000 |
| Philip Ferneau JD | Borealis Ventures | Board Member | 000 0000 |
| Stephen Squinto Ph.D | Self | Board Member | 000 0000 |
Compass Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Compass Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Compass Therapeutics Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 25-Jun-2021 | 0000000000 | 000.00 | Drug Discovery | 000000 00 |
| Olivia Ventures | 23-Jun-2020 | Merger/Acquisition | Other Capital Markets/Institutions | 000000 00 |
Compass Therapeutics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000 000000000000 | Drug Discovery | Irvine, CA | 0000 |